Diabetic retinopathy (DR) is one of the common complications associated with diabetes mellitus and the leading cause of blindness worldwide. Recent research has demonstrated that DR is not only a microvascular disease but may be a result of neurodegenerative processes. Moreover, glucose-induced neuron and glial cell damage may occur shortly after the onset of diabetes which makes the disease hard to diagnose at early stages. SIRT6, a NAD-dependent sirtuin deacylase, modulates aging, energy metabolism, and neurodegeneration. In previous studies we showed that SIRT6 deficiency causes major retinal transmission defects, changes in the expression of glycolytic genes, and elevated levels of apoptosis. Given the importance of glucose availability for retinal function and the critical role of SIRT6 in modulating glycolysis, we aimed to analyze SIRT6 participation in the molecular machinery that regulates the development of experimental DR. Using nonobese diabetic mice, we determined by western blot that 2 weeks after the onset of the disease, high glucose concentrations induced retinal increase in a neovascularization promoting factor (vascular endothelial growth factor, VEGF), and the loss of a neuroprotective factor (brain-derived neurotrophic factor, BDNF) associated with reduced levels of SIRT6 and increased acetylation levels of its substrates (H3K9 and H3K56) suggesting a deregulation of key neural factors. Noteworthy, retinas from CNS conditionally deleted SIRT6 mice showed a resemblance to diabetic retinas exhibiting lower protein levels of BDNF factor and increased protein levels of VEGF. Moreover, cultured M€ uller glial cells subjected to high glucose concentrations exhibited decreased levels of SIRT6 and increased levels of H3K56 acetylation. In addition, the increment of VEGF levels induced by high glucose was reverted by the over-expression of SIRT6 in this cell type. Accordingly, siRNA experiments showed that, when SIRT6 was silenced, VEGF levels increased. Our findings suggest that epigenetically regulated neurodegenerative events may occur at an early diabetic stage prior to the characteristic proliferative and vascular changes observed at a later diabetic stage.
Diabetic retinopathy (DR) is one of the common complications associated with diabetes mellitus and is the leading cause of blindness worldwide. Several lines of evidence indicate that shortly after the onset of the disease, retinal function is disturbed and that neurodegeneration would be an ongoing component of DR pathology, making it hard to diagnose at early stages (Lieth et al. 2000; Abcouwer and Gardner 2014) . In this context, abundant data suggest that most retinal neurons and glial cells are altered concomitantly with the development of diabetes affecting the entire neurovascular unit of the retina. These alterations include biochemical defects such as impaired neurotransmitter metabolism (Gowda et al. 2011) , loss of synaptic activity and dendrites (Gastinger et al. 2008; VanGuilder et al. 2008) , apoptosis of neurons primarily in the ganglion cell and inner nuclear layers , activation of microglial cells that may promote inflammation (Zeng et al. 2008 ) and blood-brain barrier dysfunction (Zlokovic 2008) . Consequently, early loss of neurovascular coupling, gradual neurodegeneration, gliosis, and neuroinflammation may occur before vascular pathologies become evident. Over time, neurons in the inner retinal layers lose adaptability to systemic metabolic alterations caused by diabetes and succumb to cell stress, as evidenced by a reduced axonal and dendritic branching process, axonal beading, apoptotic cell death, accumulative cell loss, and retinal layer thinning (Abcouwer and Gardner 2014) . In terms of function, evidence of defective electroretinogram response was described in patients with diabetes with no clinical signs of retinopathy (Juen and Kieselbach 1990; Tyrberg et al. 2011) . Even though considerable advances have been made in the field, the mechanisms involved in the early stages of DR remain elusive.
M€ uller cells, the principal glial cells of the vertebrate retina, play a critical role in retinal metabolism and are among the first cells to demonstrate metabolic changes in retinal stress or disease (Bringmann et al. 2006) . Activation of M€ uller cells, a process known as reactive gliosis, is associated with virtually any disease of the retina. This process promotes the survival of retinal neurons, but may also accelerate neuronal degeneration. Under hypoxia and/or impairment of glucose homeostasis conditions, M€ uller cells induce the expression and release of the vascular endothelial growth factor (VEGF) (Eichler et al. 2000) . It has been demonstrated that the production of VEGF by M€ uller cells is increased in diabetes and precedes the neovascularization observed in the diabetic human retina, when there is still no anatomical evidence of retinal mal-perfusion (Amin et al. 1997) . Moreover, M€ uller cells play an active role in the regulation of the death and survival of retinal neurons by releasing neurotrophic factors such as brain-derived neurotrophic factor (BDNF), basic fibroblast growth factor, and ciliary neurotrophic factor (Wahlin et al. 2000) . A proper comprehension of the role of M€ uller cells in the diseased retina would be crucial for the development of efficient new therapeutic strategies.
Epigenetics, inheritable changes in gene expression that do not involve modifications in the underlying DNA sequence, can serve as a link between the environment and genetic causes of disease. Epigenetic mechanisms include DNA methylation, post-translational histone modifications (methylation, acetylation, phosphorylation, etc.) and microRNA (miRNA) regulation of mRNA translation. Recent work has shown that transient hyperglycemia can induce longlasting epigenetic changes (Villeneuve and Natarajan 2010) . Thus, a diabetic environment disturbs metabolic homeostasis altering, among others, genes associated with oxidative stress, apoptosis, and inflammation (Kowluru and Chan 2010; Villeneuve and Natarajan 2010) . Moreover, epigenetic modifications of histones are considered to play a major role in the 'metabolic memory' phenomenon (Miao et al. 2014) . It has been demonstrated that diabetes-induced alterations in retinal genes do not reverse and that apoptosis continues once hyperglycemia has been terminated (Kowluru and Chan 2010) .
Current investigations focus on the role of histone acetyl transferases and deacetylases in diabetes and its complications as regulators of several key genes linked to the disease (Gray and De Meyts 2005) . SIRT6, a NAD-dependent histone deacylase, modulates aging, stress resistance, cancer, energy metabolism, neurodegeneration, and DNA repair (Mostoslavsky et al. 2006; Sebasti an et al. 2012; Toiber et al. 2013) . In previous studies we showed that SIRT6 deficiency causes major retinal transmission defects concomitant to changes in the expression of glycolytic genes and glutamate receptors, as well as elevated levels of apoptosis in inner retina cells (Silberman et al. 2014) . Given the importance of glucose availability for retinal function and the critical role of SIRT6 in modulating glycolysis, this study seeks to demonstrate that this enzime is involved in the modulation of retinal neurodegenerative processes triggered by high glucose concentrations. In this regard, we aimed to analyze SIRT6 participation in the molecular machinery that regulates the development of experimental DR.
Using the non-obese diabetic (NOD) mouse strain that spontaneously develops type 1 diabetes, we were able to determine a temporal window in which high glucose concentrations (> 200 mg/dL) induced the loss of key neuroprotective factors. At early stages of DR, we found increased retinal levels of the neovascularization inducing factor VEGF and a decrease in the neuroprotective factor BDNF with no evidence of vascular changes. In addition, we observed a reduction in SIRT6 levels associated with increased acetylation levels of its targets, H3K56 and H3K9, in retinas from NOD diabetic mice compared to normoglycemic NOD animals. Interestingly, in central nervous system conditionally deleted SIRT6 mice (Nes-Cre-SIRT6 À/À ), retinas showed a molecular resemblance to diabetic retinas, exhibiting lower levels of BDNF and increased levels of VEGF. Moreover, we found a significant decrease in SIRT6 levels and increased acetylation levels of H3K56 in high-glucose-treated M€ uller cells, suggesting that, in this cell type, SIRT6 may be down-regulated as a response to hyperglycemia. Furthermore, VEGF levels were found to be increased in high-glucose-treated M€ uller cells and this effect was reverted by the over-expression of SIRT6. Accordingly, VEGF levels increased in SIRT6 silenced cells. These findings suggest that epigenetically regulated neurodegenerative events may occur during the early development of Diabetes, prior to proliferative and hemorrhagic vascular changes observed later in a diabetic retina. Understanding the mechanisms that underlie these processes would be critical for identifying cell-specific and tissue-specific epigenetic markers and would provide a reference for the design of targeted therapies.
Methods
All animal procedures were in strict accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The ethic committee of the School of Medicine, University of Buenos Aires (Institutional Committee for the Care and Use of Laboratory Animals (CICUAL) approved this study. No blinding experiments were performed and this study was not preregistered.
Animals
NOD/ShiLtJ (NOD, RRID: IMSR_JAX:001976) female mice were from the Jackson Laboratory. All animals were kept in a pathogenfree facility under controlled conditions of light (12-12 light-dark cycle), humidity and temperature with free access to food and water. Blood glucose levels were monitored regularly with a glucose meter. NOD mice were considered diabetic when glycemic values exceeded 200 mg/dL. Normoglycemic animals were used as the control group.
Generation of SIRT6 conditional KO mice
The Sirt6 conditional targeting vector was constructed by inserting a Neo cassette (flanked by two Frt sequences) together with Sirt6 exon 2 flanked by two loxP sites. Chimeric mice were generated by injecting the targeted ES cells (V6.5) into C57BL6/J blastocysts. The Neo cassette was deleted in vivo by crossing the chimeras with a mouse expressing the Flpe endonuclease and the resulting mice were backcrossed for three generations with C57BL6/J mice (Jackson Laboratories, stock nr. 000664, Bar Harbor, ME, USA) to obtain heterozygous mice that were 97% C57BL6/J background. These mice were interbred to obtain homozygous Sirt6 fl/fl mice that were crossed with C57BL/Nestin-Cre/J mice (Jackson Laboratories, stock nr. 003771) and C57BL6/J mice expressing the Cre recombinase under Nestin promoter the Cre recombinase exposure leads to exon 2 excisions and the appearance of a premature stop codon. Both female and male mice were used.
Western blot analysis
Western blot analysis was carried out as previously described (Silberman et al. 2014) . The antibodies used were as follows: anti-SIRT6 (Abcam, Cambridge, MA, Cat# ab62739, RRID:AB_956300), anti-AcH3K9 (Abcam, Cat# ab12179, RRID:AB_298910), antiAcH3K56 (Abcam, Cat# ab76307, RRID:AB_1523762), antiHistone 3 (Abcam, Cat# ab39655, RRID:AB_732921), anti-b-actin (Sigma-Aldrich, Cat# A5316, RRID:AB_476743), anti-VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA, Cat# sc-152, RRID: AB_2212984), anti-BDNF (Santa Cruz Biotechnology, Cat# sc-546, RRID:AB_630940), anti-FLAG (Sigma-Aldrich, St. Louis, MO, USA, Cat# F1804, RRID:AB_262044).
Briefly, for histone-enriched extracts, retinas were homogenized in lysis buffer (10 mM Hepes pH 7.4, 10 mM KCl, 0.05% NP-40 plus protease inhibitors (Roche Molecular Biochemicals, Indianapolis, IN, USA). Homogenates were kept in ice for 20 min and centrifuged at 22 000 g for 10 min at 4°C. Supernatant was used for cytoplasmic protein determination and pellets were resuspended in 2-5 volumes of HCl 0.2 N and kept for 20 min on ice followed by centrifugation at 22 000 g for 10 min at 4°C. Supernatants were neutralized with 1 M TRIS-Cl pH 8 and an aliquot was used to determine protein concentration. Samples (30 lg protein/well) were separated by 4-20% gradient Trisglycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis pre-casted gel (Bio-Rad Laboratories, Hercules, CA, USA), transferred to polyvinylidene difluoride and incubated with the corresponding primary antibodies overnight at 4°C followed by secondary antibodies incubation for 1 h at room temperature (horseradish peroxidase-conjugated goat anti-rabbit (1 : 2000, catalog # 170-5046; Bio-Rad Laboratories) and visualized by enzymatic chemiluminiscence (Western Blotting Analysis System; Amersham Biosciences, Buenos Aires, Argentina). Developed membranes were scanned and the intensity of bands was determined using the ImageJ program (National Institutes of Health, Bethesda, MD, USA). Values were expressed as arbitrary units relative to b-actin or total H3.
qRT-PCR For qRT-PCR, total RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and cDNA was generated using QuantiTect Reverse Transcription Kit (Qiagen) according to manufacturer instructions. qPCR was carried out using Brilliant SYBR Green qPCR Master Mix Kit (Stratagene, La Jolla, CA, USA). Data were calculated using the DCt method. Primers used were as follow:
Morphologic analysis Anesthetized mice were intracardiacally perfused with 4% paraformaldehyde as previously described (Fernandez et al. 2013) . Eyes were removed, immersed for 24 h in the same fixative, embedded in paraffin and sectioned (5 lm). Cross sections were stained with hematoxylin and eosin and used for morphometric analysis. Thickness of the total retina as well as the individual layers was measured for each eye. Results obtained from four separate sections were averaged and the mean of six eyes was recorded as the representative value for each group.
Immunoflourescence protocol
For cultures, cells were fixed with 4% paraformaldehyde for 10 min, permeabilized within 0.1% Triton X-100 in 0.1 M phosphatebuffered saline for 10 min and blocked with 5% normal horse serum for 1 h at 18-22°C. Cells were incubated overnight at 4°C with the corresponding primary antibodies [anti acetyl H3K56 antibody (dil 1 : 500; Abcam), anti-glutamine synthetase (1 : 250; Millipore Corporation, Bedford, MA, USA)] and secondary antibody for 1 h at 18-22°C (Alexa Fluor â 555 Goat Anti-Mouse IgG, 1 : 500, Alexa Fluor â 488 Goat Anti-rabbit IgG, 1 : 500). As a control, some wells were treated without primary antibodies regularly. 4 0 ,6-diamidino-2-phenylindole was used after immunostaining to stain nuclei and a fluorescence microscope was used to visualize the mark. For retinas, paraffin-embedded tissues were sectioned and treated as previously described (Fernandez et al. 2013) . After deparaffinization, cross sections were immersed in 0.1% Triton X-100 in 0.1 M phosphate-buffered saline for 10 min and antigen retrieval was performed by heating at 90°C for 30 min in citrate buffer (pH 6.3). Sections were blocked and incubated overnight at 4°C with the corresponding primary antibodies as described for cells.
M€ uller cells enriched primary culture
Purified cultures of M€ uller glial cells were prepared using adapted protocols previously described (Sim on et al. 2015) . Briefly, eyes from 3-to 4-day-old female CD1 mice pups were excised and incubated overnight in Dulbecco's modified Eagle's medium (DMEM) (Gibco) at 18-22°C and then treated with trypsin (1 mg/mL; Gibco, Rockville, MD, USA) and type 2 collagenase (2 mg/mL; Sigma, St Louis, MO, USA) for 10 min at 37°C. Retinas were then dissected, chopped into small pieces, and seeded in DMEM culture medium (Gibco, Low glucose: 5.5 mM) supplemented with 10% fetal bovine serum, Penicilin/Streptomycin and Glutamax (Gibco). The medium was replaced every 3-4 days. M€ uller cell phenotype was confirmed by the expression of characteristic glial markers such as glutamine synthetase and CRALBP ( Figure S1 ). Highly enriched M€ uller glial cells cultures were used when they became 80% confluent. High glucose treatment was accomplished by replacing the media for DMEM High-Glu (Gibco, High glucose: 25 mM) 48 h prior to determinations.
Transient transfection
For both over-expression and silencing experiments M€ uller cells were transiently transfected using Lipofectamine 2000 according to manufacturer 0 s instructions. Briefly, the CMV-S6WTFLAG plasmid carrying the wild-type sequence of sirt6 was used for the overexpression experiments. The plasmid CMV-FLAG was used as a control. High glucose treatment was induced 24 h after the transfection by replacing the culture media and cells were collected 48 h after for determinations. SIRT6 siRNA (Sigma-Aldrich, #EMU02471) or siRNA Universal Negative control (Sigma-Aldrich, #SIC001) were used for silencing experiments. Cells were collected 48 h post-transfection for determinations.
Statistical analysis
Normality of data was assessed by the Shapiro-Wilk's test prior to the analysis. Quantitative data were expressed as means AE SEM of values obtained from the 'n' described in each figure. Student's t-test was used and differences were considered significant at p < 0.05.
Results
Deregulation of key neural factors in early stages of Diabetic Retinopathy The non-obese diabetic (NOD) mouse strain spontaneously develops hyperglycemia and is a well-recognized model for type 1 diabetes (T1D). As shown in Fig. 1 , hyperglycemia starts to be detected by the age of 10 weeks in our colony. Histological analysis of the retinas from animals killed 2-3 weeks from the onset of hyperglycemia showed no signs of vascular abnormalities, edema, or detachment compared to the control group (Fig. 1) . However, the levels of vascular endothelial growth factor (VEGF), a neovascularizationpromoting factor which is known to be an important contributor to the progression of DR, were found to be increased in NOD diabetic retinas compared to controls (Fig. 2) . This result suggests that favorable conditions for the imminent blood-retinal barrier disruption are in motion. In addition, brain-derived neurotrophic factor (BDNF) levels, a neurotrophin that mediates induction of neurogenesis and neuronal differentiation preventing neuronal damage during pathologic conditions, were decreased in NOD diabetic retinas (Fig. 2) . These results indicate a time lapse in which, despite the lack of microvascular complications, the deregulation of key neural factors is already in progress.
Histone deacetylase SIRT6 is down-regulated in NOD diabetic retinas As mentioned, SIRT6 is a NAD-dependent histone deacetylase known to be a key modulator of glucose metabolism ). When we analyzed SIRT6 protein and mRNA levels, we found a significant decrease in NOD diabetic retinas. In addition, we observed an increase in the acetylation levels of two SIRT6 known substrates, H3K56 and H3K9 in NOD diabetic retinas compared to NOD normoglycemic mice (Fig. 3 and Figure S2 ).
SIRT6 deficiency and retinal neurodegenerative processes
We have previously described that SIRT6 has a critical role in the mouse retina (Silberman et al. 2014) . We determined that SIRT6 deficiency has no effects on retinal structure but causes major retinal transmission defects and alters the expression of glucose homeostasis related genes as well as glutamate receptors. However, these determinations were made in whole-body SIRT6-KO mice, which develop a severe metabolic phenotype, causing these animals to die early in life (Mostoslavsky et al. 2006) . To analyze SIRT6 deficiency in adulthood we used central nervous system conditionally deleted SIRT6 knockout mice (Nes-Cre-SIRT6
À/À
). These mice develop normally, allowing the analysis of SIRT6 deficiency in the CNS in different stages of life. SIRT6 levels were determined in 2-month-old animals by western blot to confirm that ablation was accomplished. As a consequence of SIRT6 deletion, H3K56 and H3K9 acetylation levels in the retina of NesCre-SIRT6 À/À mice were significantly increased (Fig. 4) .
Interestingly, immunofluorescence analysis showed that the increased acetylation mark of H3K56 was located mostly in the inner nuclear layer where nuclei from M€ uller cells reside (Fig. 4) . The histological analysis of the retinas revealed no vascular abnormalities. However, whole retinal thickness from Nes-Cre-SIRT6 À/À mice, as well as some of the individual retinal layers were thinner compared to SIRT6 +/+ controls ( Fig. 5) , suggesting an ongoing neurodegenerative process. Notably, as observed in NOD diabetic retinas, VEGF levels were increased and BDNF levels were decreased in Nes-Cre-SIRT6 À/À retinas (Fig. 6 ). This result would reinforce the idea of an ongoing neurodegenerative process.
SIRT6 regulation of neural factors in M€ uller glial cells
Retinal M€ uller cells are a critical source of growth factors, including VEGF. Activation of M€ uller cells is a process that supports the survival of retinal neurons but, if persists, it may accelerate the progress of neuronal degeneration. We evaluated SIRT6 protein levels and the acetylation status of H3K56 in M€ uller cells enriched primary cultures subjected to a high glucose concentration (25 mM). We found decreased . Protein levels of the neovascularization-promoting factor were increased, whereas a significant decrease in the neuroprotective factor was observed in NOD diabetic retinas versus NOD controls. Data are mean AE SE (n = 6 eyes/group) **p < 0.01.
levels of SIRT6 and a significant increment of H3K56 acetylation levels after 48 h treatment that would suggest a down-regulation of SIRT6 expression in this cell type (Fig. 7) . We further explored SIRT6 involvement in the mechanisms that regulate neural factors levels in M€ uller cells by analyzing VEGF and BDNF levels. Notably, we observed that VEGF levels increased significantly in M€ uller cells under high glucose concentration and decreased to control values when SIRT6 was over-expressed (Fig. 7) . Accordingly, acetylation levels of H3K56 diminished in SIRT6 over-expressing cells. Furthermore, SIRT6 silencing resulted in the increment of VEGF levels supporting the idea of SIRT6 as a direct modulator of this vascular factor (Fig. 8) . We also found that high glucose induced a decrease in BDNF levels, whereas this effect was reverted in SIRT6 overexpressing M€ uller cells (Fig. 7) . However, BDNF levels did not show significant variations in SIRT6 siRNA expressing cells compared to controls (data not shown).
Discussion
Diabetic retinopathy is a major complication of diabetes and is widely considered to be a neurovascular disease. Several cellular and molecular studies both in patients with DR and animal models indicate that retinal neurons are susceptible to damage shortly after the onset of the disease. This vulnerability exists before any sign of vascular damage . It is currently accepted that neurodegeneration participates in early microvascular changes that occur in DR such as the blood-retinal barrier breakdown (via glutamate mediated excitotoxicity that stimulates VEGF release), and impairment of neurovascular coupling (Simo and Hernandez 2014) . Moreover, evidence of retinal functional impairment like defective electroretinographic response has been described in patients with diabetes with no clinically diagnosed retinopathy (Juen and Kieselbach 1990; Tyrberg et al. 2011) . Thus, it would be of paramount importance to identify early diagnostic markers that could serve to prevent the onset of the disease or arrest its progression at a stage that precedes the appearance of manifested microvascular pathologies. In this regard, and taking advantage of a well recognized mouse model of type I diabetes, we were able to determine a temporal window in which systemic hyperglycemia is accompanied by molecular signs of retinal neurodegeneration. Although no symptoms of Fig. 3 NAD+ dependent histone deacetylase SIRT6 is down-regulated in NOD diabetic retinas. Representative western blot of SIRT6 and acetylation level of its substrates H3K9 and H3K56 in NOD control (NOD C) and NOD diabetic (NOD Diab) retinas. Band quantification was performed using b-actin and total H3 for normalization. Data are mean AE SE (n = 6-8 eyes/group). *p < 0.05, **p < 0.01. vascular abnormalities were observed, we detected a retinal increase in a neovascularization promoting factor (VEGF) and the loss of a neuroprotective factor (BDNF). Moreover, we found at this stage that SIRT6, a well-known epigenetic metabolic modulator which we previously shown to influence retinal function (Silberman et al. 2014) , was already down-regulated. VEGF has been extensively investigated for its possible involvement in diabetic vascular complications (Aiello and Wong 2000) . There is abundant evidence to support that poor glycemic control in diabetic patients is associated with increased plasma levels of VEGF, which in turn may cause hypertension and several vascular complications. Circulating VEGF levels were found to be increased in children and young adults with type 1 diabetes mellitus and middle-aged diabetic patients with proliferative retinopathy (Chiarelli et al. 2000) . Moreover, increased VEGF levels were observed in the vitreous of patients with proliferative DR (Cheung et al. 2014 ). In our model we found an increment of VEGF levels in retinas from NOD diabetic mice, indicating that an angiopathic process may already be at play, before clinical symptoms are observed.
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin growth factor family that induces neurogenesis and neuronal differentiation, promotes neuronal growth and survival, and maintains synaptic plasticity and neuronal interconnections. Several studies have shown a downregulation of its expression during Diabetes, thereby rendering neurons vulnerable to the damages produced by hyperglycemia-induced alteration (Behl and Kotwani 2016) . In this context, we observed BDNF levels to be decreased in retinas from NOD diabetic mice suggesting a loss of the neuroprotective capacity and reinforcing the idea of an ongoing neurodegenerative process. Outer Plexiform Layer (OPL), Outer Nuclear Layer (ONL), Retinal Pigment Epithelium (RPE). *p < 0.05, **p < 0.01 (n = 6-8 eyes/ group).
Fig. 6
Representative western blot of vascular endothelial growth factor (VEGF) (a) and brain-derived neurotrophic factor (BDNF) (b). As shown for non-obese diabetic mice, protein levels of the neovascularizationpromoting factor (VEGF) were increased, whereas a significant decrease in the neuroprotective factor (BDNF) was observed in retinas from Nes-Cre-SIRT6 À/À versus NesCre-SIRT6 +/+ mice. Data are mean AE SE (n = 4 eyes/group), **p < 0.01.
Recent studies have shown that transient hyperglycemia induce longlasting epigenetic changes. Thus, epigenetic modifications of histones are considered to play a major underlying role in the 'metabolic memory' phenomenon (Villeneuve et al. 2008) . Several studies have shown that alterations in retinal genes induced by diabetes do not reverse, and that triggered apoptotic processes continue even after hyperglycemia has terminated (Kowluru and Chan 2010; Zhong and Kowluru 2010) . SIRT6 is a chromatin-bound protein from a family of NAD (+)-dependent deacetylases that plays a key role in metabolism by co-repressing glycolitic genes. In our model, SIRT6 retinal levels were significantly decreased in NOD diabetic mice compared to NOD normoglycemic littermates. In accordance with this finding, we observed increased levels of acetylation of two SIRT6 known substrates, H3K9 and H3K56. Our results support other groups' findings that observed decreased SIRT6 levels in pancreatic islets from diabetic mice (Xiong et al. 2016) and in carotid plaques of asymptomatic diabetic patients (Balestrieri et al. 2015) . Moreover, SIRT6-over-expressing mice were found to be protected from developing high-caloric-dietinduced hyperglycemia and glucose intolerance (Anderson et al. 2015) . Conversely, increased SIRT6 levels were found in hepatocytes from NOD diabetic mice (Ghiraldini et al. 2013) . More studies will be required to fully elucidate SIRT6 involvement in metabolic diseases.
In a previous work, we described a unique role for SIRT6 in the retina (Silberman et al. 2014) . We found that retinas from SIRT6 deficient mice showed major retinal function impairment accompanied by changes in the expression of glycolytic genes and glutamate receptors and increased levels of apoptosis in the inner retinal layers. These studies were made in SIRT6 whole-body knockout mice that, owing to the severe metabolic phenotype, die perinatally making the study of SIRT6 deficiency impossible to perform in adulthood. In this regard, a recent a study conducted in aged SIRT6 À/À showed an age-dependent progressive impairment of retinal function accompanied by thinning of retinal layers (Peshti et al. 2017) . However, this study used mice generated in a mixed genetic background so the phenotype induced by a single gene mutation would bias the observations reported. To analyze the effect of SIRT6 absence in adult mice, we used CNS conditionally deleted SIRT6 knockout mice (NesCre-SIRT6 À/À ). Remarkably, we found a molecular resemblance between retinas from Nes-Cre-SIRT6 À/À mice and retinas from NOD diabetic animals. We found increased VEGF levels and decreased BDNF levels in Nes-Cre-SIRT6 À/À retinas and, although no evident vascular abnormalities were observed, a significant reduction in the whole retinal thickness as well as some specific individual layers was observed suggesting an ongoing neurodegenerative process. Moreover, a recent report showed that brain-specific SIRT6 deficiency causes behavioral defects, increased sings of DNA damage, cell death and hyper-phosphorylation of the Tau protein, a critical marker of several neurodegenerative diseases (Kaluski et al. 2017) . Further studies are required to evaluate SIRT6 as a potential therapeutic target in neurodegenerative disorders. M€ uller cells are the principal glial cells of the vertebrate retina and play critical roles in supporting neuronal function (Bringmann et al. 2006) . Under pathological conditions these cells become reactive exerting morphological, biochemical, and physiological changes that vary with the type and severity of the insult. In DR, up-regulation of insulin-like growth factor 1 and hypoxia and inflammation induced factors promote the activation of M€ uller cells that in turn release VEGF and basic fibroblast growth factor stimulating pathological neovascularization and retinal fibrosis (Rodrigues et al. 2013). We found that a high glucose stimulus, as short as 48 h, was capable of inducing a decrease in SIRT6 protein levels concomitant with an increase in the acetylation levels of one of the well-recognized SIRT6 substrate, H3K56, in M€ uller cells enriched primary cultures. These results suggest that, in this cell type, SIRT6 may be downregulated as a response to hyperglycemia. In addition, we determined that a high glucose concentration induced an increase in VEGF levels that returned to control values in SIRT6 over-expressing cells. Accordingly, we observed that VEGF levels augmented in SIRT6 siRNA expressing cells suggesting a direct role of SIRT6 as a VEGF modulator. SIRT6 decrease or absence would explain the up-regulation of the vascular factor and would suggest SIRT6 as a repressor of this gene. To elucidate the mechanism/s by which SIRT6 may regulate the expression of VEGF we analyzed chromatin immunoprecipitation (ChIP) data from our previous paper on embryonic stem cells (Etchegaray et al. 2015) and found that SIRT6 is bound to the promoter regions of VEGF strongly suggesting that it would act as a direct regulator ( Figure S3 ). Although this observation will require a proper validation in M€ uller cells, it is likely that a similar mechanism would be involved in this cell type. Thus, this modulation could be exerted directly through a repressive transcription factor-like mechanism or, most likely, as the consequence of the derepression of HIF1a owing to the decrease in SIRT6 levels. Since HIF-1a is the most important known regulator of VEGF transcription, and SIRT6 was described to co-repress HIF-1a by deacetylating H3K9 at HIF-1a target gene promoters , VEGF increment observed in high-glucose-treated glial cells could be explained by the reduction in SIRT6 levels resulting in the derepression of HIF1a and the concomitant increase in histone acetylation, that ultimately causes increased expression of the VEGF gene. Further studies will be required to confirm either possibility.
We also observed that a high glucose concentration induced a decreased in BDNF levels in cultured M€ uller glial cells. These levels were significantly increased in SIRT6 over-expressing cells. However, the participation of SIRT6 may be indirect and involve other players since the decrease in the neurotrophic factor levels was not observed when we knocked-down SIRT6. In fact, no significant variations of BDNF were observed in SIRT6 silenced cells. Additional studies will be necessary to elucidate SIRT6 involvement in BDNF regulation.
Identification of epigenetic modifications associated with diabetes may contribute to the early detection of high-risk individuals. Furthermore, finding cell-specific and tissuespecific epigenetic markers would provide a reference for designing targeted therapies and would help to understand the role of epigenetic factors in the regulation of neurodegenerative processes. All experiments were conducted in compliance with the ARRIVE guidelines.
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